1. KD Tripathi MD. Insulin, oral hypoglycaemic drugs and glucagon: Hormones and related drugs. Essentials of Medical Pharmacology 7th ed. New Delhi, May 2013. Page - 275.
2. Powers AC, D Alessio D. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. Page - 1264.
3. Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. Page - 1248 - 1249.
4. Darshan J. Dave. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus: Journal of pharmacology and pharmacotherapeutics, Oct-Dec 2011; [Accessed Nov 17, 2020] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198516/#:~:text=Saxagliptin%2C%20a%20reversible%2C%20competitive%20dipeptidyl,and%20decreases%20secretion%20of%20glucagon
5. AstraZeneca UK Limited, Electronic Medicines Compendium (EMC) [Revised March 2020] [Accessed Nov 17, 2020] https://www.medicines.org.uk/emc/files/pil.6675.pdf
6. AstraZeneca Pharmaceuticals LP, 2009; U.S. Food & Drug Administration [Accessed Nov 17, 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022350s018lbl.pdf
7. AstraZeneca AB. [Accessed Nov 17, 2020] https://www.ema.europa.eu/en/documents/product-information/onglyza-epar-product-information_en.pdf